Tenax Therapeutics Inc

NASDAQ:TENX   3:58:05 PM EDT
0.39
+0.08 (+25.64%)
Products, Regulatory

Tenax Announces Successful Comparative Pharmacokinetic Study Of Pulmonary Arterial Hypertension Treatment

Published: 05/23/2022 13:18 GMT
Tenax Therapeutics Inc (TENX) - Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of Tnx-201 for the Treatment of Pulmonary Arterial Hypertension.
Tenax Therapeutics Inc - Manufacturing Underway to Support Phase 3 Pah Study (improve).
Tenax Therapeutics Inc - Clinical Sites Are Now Being Recruited, With Patient Enrolment Expected to Start in 2h 2022.